To evaluate further the utility of these markers for differentiating patients with GC from controls, we next determined the ORs and confirmed that increased levels of IL-1β, IL-6, IFN-γ, and IL-10 were all associated with increased risk of GC, noting that high levels of IL-6 increased the risk of current GC 17.9 times. Here, IL1B is linked to gastric cancer.